Altogether, our results demonstrate the feasibility of oral administration of a cathepsin S inhibitor and its potential usefulness in ameliorating age-associated dry eye while shedding light on the underlying therapeutic mechanisms. The gene discussed is CTSS; the disease is Keratoconjunctivitis sicca.